Next Article in Journal
HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia
Previous Article in Journal
Dysregulation of Natural Killer Cells in Obesity
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle

Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer

1
Center for Breast cancer, National Cancer Center, Goyang 10408, Korea
2
Division of Translational Science, National Cancer Center, Goyang 10408, Korea
3
Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea
4
Division of Convergence Technology, National Cancer Center, Goyang 10408, Korea
5
Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center, Goyang 10408, Korea
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2019, 11(4), 574; https://doi.org/10.3390/cancers11040574
Received: 15 March 2019 / Revised: 16 April 2019 / Accepted: 19 April 2019 / Published: 23 April 2019
  |  
PDF [3826 KB, uploaded 23 April 2019]
  |  

Abstract

Patient-derived xenografts (PDXs) are powerful tools for translational cancer research. Here, we established PDX models from different molecular subtypes of breast cancer for in vivo drug tests and compared the histopathologic features of PDX model tumors with those of patient tumors. Predictive biomarkers were identified by gene expression analysis of PDX samples using Nanostring nCount cancer panels. Validation of predictive biomarkers for treatment response was conducted in established PDX models by in vivo drug testing. Twenty breast cancer PDX models were generated from different molecular subtypes (overall success rate, 17.5%; 3.6% for HR+/HER2, 21.4% for HR+/HER2+, 21.9% for HR/HER2+ and 22.5% for triple-negative breast cancer (TNBC)). The histopathologic features of original tumors were retained in the PDX models. We detected upregulated HIF1A, RAF1, AKT2 and VEGFA in TNBC cases and demonstrated the efficacy of combined treatment with sorafenib and everolimus or docetaxel and bevacizumab in each TNBC model. Additionally, we identified upregulated HIF1A in two cases of trastuzumab-exposed HR/HER2+ PDX models and validated the efficacy of the HIF1A inhibitor, PX-478, alone or in combination with neratinib. Our results demonstrate that PDX models can be used as effective tools for predicting therapeutic markers and evaluating personalized treatment strategies in breast cancer patients with resistance to standard chemotherapy regimens. View Full-Text
Keywords: patient-derived xenograft; breast cancer; pre-clinical drug test; personalized therapy; sorafenib; everolimus; docetaxel; bevacizumab; PX-478; neratinib patient-derived xenograft; breast cancer; pre-clinical drug test; personalized therapy; sorafenib; everolimus; docetaxel; bevacizumab; PX-478; neratinib
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Ryu, J.-S.; Sim, S.H.; Park, I.H.; Lee, E.G.; Lee, E.S.; Kim, Y.-H.; Kwon, Y.; Kong, S.-Y.; Lee, K.S. Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. Cancers 2019, 11, 574.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top